EGFR and non-small cell lung carcinoma: In squamous NSCLC (Keynote-407 trial) and non-squamous NSCLC (Keynote-189 trial), first-line combination therapies that integrate immunotherapies with chemotherapy have shown remarkable clinical efficacy in patients with no sensitizing EGFR or ALK mutations [18].